Three F.D.A. Advisers Resign Over Approval of Alzheimer's Drug June 10, 2021 000 per year a monthly infusion priced at $56 Aduhelm IFTTT NYT NYT > Business NYTimes The drug was approved this week despite weak evidence that it helps patients. +
Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense June 08, 2021 Aduhelm Despite scant evidence that it works IFTTT is predicted to generate billions of dollars in revenue much of it from Medicare. NYT NYT > Business NYTimes The drug +